Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.57 |
| ▸ | USP8 | P40818 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879530 | 0.89 | ACLY (0.52) | USP2USP8KMT2AACLYKDM1A | |
| SCHEMBL24268165 | 0.84 | KDM1A (0.51) | USP2USP8KMT2AACLYKDM1A | |
| SCHEMBL23879571 | 0.83 | KDM1A (0.50) | USP2USP8ACLYKDM1AUSP36 | |
| SCHEMBL23879629 | 0.83 | KDM1A (0.50) | USP2USP8ACLYKDM1AUSP36 | |
| SCHEMBL24268128 | 0.82 | KDM1A (0.49) | USP2USP8ACLYKDM1AUSP36 | |
| SCHEMBL23879544 | 0.82 | KDM1A (0.49) | USP2USP8ACLYKDM1AUSP36 | |
| SCHEMBL23879572 | 0.81 | MCL1 (0.44) | KMT2AACLYKDM1AMCL1KDM4E | |
| SCHEMBL23879609 | 0.81 | KDM1A (0.48) | USP2USP8KMT2AACLYKDM1A | |
| SCHEMBL24268146 | 0.81 | KDM1A (0.48) | USP2USP8ACLYKDM1AUSP36 | |
| SCHEMBL25140639 | 0.80 | USP2 (0.66) | USP2USP8KMT2AACLYSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | USP2 3178/4885USP8 3142/4885KMT2A 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.